key: cord-0260945-x8zdd3gk
authors: Poppelaars, F.; Gaya da Costa, M.; Eskandari, S. K.; Damman, J.; Seelen, M. A.
title: Donor genetic variants in interleukin-6 and interleukin-6 receptor associate with biopsy-proven rejection following kidney transplantation.
date: 2021-04-22
journal: nan
DOI: 10.1101/2021.04.17.21255669
sha: 2d769e68a385678c1d5a5241a8521d76670cc3b7
doc_id: 260945
cord_uid: x8zdd3gk

Rejection after kidney transplantation remains an important cause of allograft failure that markedly impacts morbidity. Cytokines are a major player in rejection, and we, therefore, explored the impact of interleukin-6 (IL6) and IL-6 receptor (IL6R) gene polymorphisms on the occurrence of rejection after renal transplantation. We performed an observational cohort study analyzing both donor and recipient DNA in 1,271 renal transplant-pairs from the University Medical Center Groningen in The Netherlands and associated single nucleotide polymorphisms (SNPs) with biopsy-proven rejection after kidney transplantation. The C-allele of the IL6R SNP (Asp358Ala: rs2228145 A>C, formerly rs8192284) in donor kidneys conferred a reduced risk of rejection following renal transplantation (HR 0.78 per C-allele; 95%-CI 0.67-0.90; P=0.001). On the other hand, the C-allele of the IL6 SNP (at position-174 in the promoter; rs1800795 G>C) in donor kidneys was associated with an increased risk of rejection for male organ donors (HR per C-allele 1.31; 95%-CI 1.08-1.58; P=0.0006), but not female organ donors (P=0.33). In contrast, neither the IL6 nor IL6R SNP in the recipient showed an association with renal transplant rejection. In conclusion, donor IL6 and IL6R genotypes but not recipient genotypes represent an independent prognostic marker for biopsy-proven renal allograft rejection.

Since the first successful kidney transplant in 1954, kidney transplantation has become the treatment of 2 choice for patients with end-stage kidney disease (ESKD). 1 Beyond the surgical advances in performing 3 kidney transplantation, it was the addition of immunosuppressive drugs post-transplant that improved 4 the survival of kidney allografts from months to years. Transplant recipients, however, invariably become 5 sensitized to their transplant, leading to poor long-term survival of kidney allografts. 2,3 While 6 conventional immunosuppressants are effective at abolishing acute immune responses, they only 7 partially address allosensitization-thus allowing humoral immunity to form and precipitate long-term 8 allograft failure. To prevent rejection of kidney transplants it is thus necessary to develop novel therapies 9 that can impede the formation of allosensitization. 4 10 Through the scientific efforts of the past fifty years, it has been established that acute and 11 chronic allograft rejection are triggered by a complex and dynamic set of alloimmune responses.

Immunomodulatory proteins known as cytokines are particularly important in regulating both the pro-13 and anti-inflammatory arms of immunity. Among all cytokine superfamilies, interleukin 6 (IL-6) and its 14 family members arguably show the greatest degree of cytokine functional pleiotropy (multiple biological 15 actions) and cytokine redundancy (shared biological actions), with physiological and pathological roles 16 ranging from B and T cell differentiation and acute-phase immunity, to hematopoiesis and oncogenesis, 17 tissue and bone remodeling and regeneration, and even early development of neuronal and 18 cardiovascular systems. 5-8 As such, aberrant IL-6 activity is implicated in diseases including systemic 19 inflammatory response syndrome, chronic immune disorders such as crescentic glomerulonephritis, 20 transplant rejection, and graft-versus-host disease, rheumatic diseases including rheumatoid arthritis 21 and juvenile idiopathic arthritis, and lymphoproliferative conditions like Castleman's disease. 4, 8, 9 22 Emerging data has identified a key role for IL-6 in rejection after renal transplantation. 4 In order 23 to appreciate the role of IL-6 signalling in renal allograft rejection, it is of value to contextualize the 24 signalling cascade first as IL-6 can signal through three separate pathways and command varying 25 effects depending on the context and the pathway at play. 5,6,10 The first mode of signaling is known as 26 classic signaling, in which IL-6 binds to membrane-bound IL-6 receptor (mIL-6R) followed by complex 27 formation with membrane-bound glycoprotein 130 (gp130) to trigger downstream signal transduction 28 and gene expression. Trans signaling instead occurs when the IL-6R is cleaved from the cell 29 membrane, 10 and the released soluble IL-6R (sIL-6R) captures IL-6, forms a complex with membrane-30 bound gp130, and phosphorylates intracellular signal transducers. Since membrane-bound gp130 is 31 ubiquitously expressed but mIL-6R is not, trans signaling can facilitate IL-6 responsivity in cells that 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint

Determinants of biopsy-proven rejection following kidney transplantation.

A total of 1,271 kidney transplant donor-recipient pairs were included in this study with the donor and 4 recipient characteristics listed in Table 1 . The mean follow-up after transplantation was 5.2 years ± 5.0 5 with a maximum follow-up period of 16.7 years. During follow-up, 33.8% of the recipients developed 6 biopsy-proven rejection. In the first year, 390 recipients developed acute biopsy-proven rejection, 7 whereas 40 recipients presented with biopsy-proven rejection thereafter. Of all the assessed 8 characteristics, the following were significantly associated with biopsy-proven rejection (Table 1) ; 9 recipient age, recipient sex, warm ischemia time, the total number of HLA mismatches, and the 10 occurrence of delayed graft function (DGF).

A common genetic variant in interleukin-6 receptor protects against renal allograft rejection.

To identify relevant genetic biomarkers in the context of rejection, we explored whether the Asp358Ala 14 variant in IL6R (rs2228145 A>C, previously rs8192284) associated with biopsy-proven rejection. The 15 observed genotype frequencies in recipients (n=1270; AA, 34.3%; AC, 51.4%; CC, 14.2%) and donors 16 (n=1269; AA, 35.6%; AC, 50.6%; CC, 13.6%) were comparable (P = 0.75). Yet, the frequencies of the 17 IL6R polymorphism in both recipients and donors were significantly higher than reported by the 1000 18 genomes project (P<0.0001), but not when compared to their European cohort (P = 0.09). 15 Kaplan-

Meier survival analyses showed that the IL6R polymorphism in the donor was significantly associated 20 with a reduced risk for acute rejection during follow-up ( Fig. 1A ; log-rank P = 0.003). After the complete 21 follow-up, the incidence of biopsy-proven rejection was 38.9% in the reference AA genotype group, 32.8% 22 in the heterozygous AC genotype group, and 24.9% in the homozygous CC genotype group, 23 respectively. In the recipients, Kaplan-Meier survival analyses revealed no associations between the 24 IL6R SNP and rejection during follow-up (Fig 1B; log-rank P = 0.70). Subgroup analysis for recipient sex 25 or donor type did not change these results. In univariate analysis, the IL6R SNP in the donor was 26 associated with a hazard ratio of 0.78 per C-allele (95%-CI: 0.67 -0.90; P = 0.001) for biopsy-proven 27 rejection. A multivariable analysis was performed to adjust for potential confounders (Table 2) 

In Cox regression analysis, the IL6R SNP in the donor remained significantly associated with biopsy-30 proven rejection independent of potential confounders. Finally, we performed a multivariable analysis 31 with a stepwise forward selection procedure using all variables associated with rejection in univariable 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint analysis (Table 3 ). In the final model, the IL6R SNP in the donor, recipient age and sex, the total number 1 of HLA mismatches, and DGF were included. After adjustment, the IL6R SNP in the donor was 2 associated with rejection with a hazard ratio of 0.73 per C-allele (95% CI: 0.62 -0.86, P<0.001). Hence, 3 altogether these results demonstrate that a common functional variant in the IL6R gene in the donor 4 associates with a lower incidence of biopsy-proven acute rejection after kidney transplantation.

A common genetic variant in interleukin-6 is a risk factor for renal allograft rejection.

Next, we explored whether the IL6 SNP at position-174 in the promoter (rs1800795 G>C) affects the 8 incidence of biopsy-proven rejection. The observed genotype frequencies in the recipients (n=1268: GG, 9 37.8%; GC, 47.0%; CC, 14.9%) and donors (n=1260: GG, 33.1%; AC, 49.3%; CC, 16.8%) differed 10 significantly (P = 0.049). More specifically, the C-allele of the IL6 SNP seemed to be more prevalent in 

We next performed a subgroup analysis for sex, since sex is known to impact immunity, renal 18 disease as well as transplantation outcome. 16,17 Kaplan-Meier curves revealed a significant association 19 between the IL6 SNP and rejection in male donors (Fig. 2C , P = 0.015). After the complete follow-up, 20 the incidence of biopsy-proven rejection was 27.1% in the reference GG genotype group, 37.3% in the 21 heterozygous GC genotype group, and 40.7% in the homozygous CC genotype group, respectively. No association was seen between the IL6 SNP and rejection in female donors ( Fig. 2D , P = 0.33). Univariate 23 analysis revealed that the IL6 SNP in male donors was associated with a hazard ratio of 1.31 per C-24 allele (95%-CI: 1.08 -1.58; P = 0.006) for biopsy-proven rejection. Multivariable analysis was performed 25 to adjust for potential confounders (Table 2) , including donor characteristics (model 2), recipient 26 characteristics (model 3), and transplant variables (model 4). In Cox regression analysis, the IL6 SNP 27 in male donors remained significantly associated with biopsy-proven rejection independent of potential 28 confounders. Thus, it appears that a functional variant in IL6 in male donors is linked to a higher 29 incidence of biopsy-proven rejection after kidney transplantation.

Prediction of biopsy-proven rejection 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint 1 of the same SNP in the donor and recipient of a transplant pair (Fig. 3C -D) . We, therefore, speculated 2 that assessing the combined presence of multiple polymorphisms, a genetic risk score, in the donor-3 recipient pairs could yield more information than examining the polymorphisms individually. To explore 4 the combination of IL6 and IL6R SNPs as predictors of biopsy-proven rejection, we created a genetic 5 risk score of the two variants in both the donors and recipients. Weight was added to each SNP 6 according to their hazard ratio, creating a negative score for protective polymorphisms and a positive 7 score for hazardous ones. Overall, a genetic risk score above zero indicates the presence of more 8 hazardous SNPs in a donor-recipient pair and genetic risk scores below zero indicate the presence of 9 more protective SNPs in a donor-recipient pair. To assess the clinical applications of the IL-6/IL-6R 10 genetic risk score, we studied the predictive value of this genetic profiling in more detail. The genetic 11 risk score was significantly associated with biopsy-proven rejection in both the crude model (HR, 1.24; 12 95%-CI, 1.12 -1.36; P<0.001 per SD increase) and after adjustment for donor characteristics, recipient 13 characteristics, and transplant variables (Table 4) . Furthermore, the hazard ratio of the IL-6/IL-6R showed substantial overlap with the overall hazard ratio at the top, demonstrating the consistency of the 17 findings across subgroups. Next, we tested if the IL-6/IL-6R genetic risk score was a better predictor for 18 rejection than the IL-6R SNP in the donor by multivariable regression with a stepwise forward selection 19 was performed (Table 5 ). In the final model, the IL-6/IL-6R genetic risk score was included whereas the 20 IL6R SNP in the donor was not. After adjustment, the genetic risk score in the donor was associated 

The performance of the IL-6/IL-6R genetic risk score for the prediction of rejection was also 24 assessed ( Table 6 ). The genetic risk score alone had a Harrell's C of 0.57 (95% CI: 0.54 -0.60). 

the IL-6/IL-6R genetic risk score significantly improved the predictive value of the models according to 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint the integrated discrimination improvement index (IDI). Even in the fully adjusted models, the IDI value 1 was >1%, indicating that the IL-6/IL-6R substantially improved risk prediction for rejection markedly 2 beyond currently used clinical markers.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint Discussion 1 Rejection after kidney transplantation remains an important cause of allograft failure that greatly impacts 2 morbidity. 18-20 Use of novel therapies to reduce allosensitization is vital, but new drug development for 3 kidney transplantation is limited, 21 necessitating the repurposing of existing anti-inflammatory drugs 4 approved for other indications. Among these are IL-6-blocking therapies, which have already been 5 approved for the treatment of auto-immune diseases. 22 Human genetics offer an opportunity for target 6 validation. Moreover, drug targets informed by human genetic evidence are more than twice as likely to 7 lead to approved therapeutics. 23, 24 The main finding of our study is a significant association between a 8 common functional IL6 and IL6R polymorphisms in the donor and the risk of biopsy-proven rejection 9 following kidney transplantation. Extending these findings, a genetic risk score based on both SNPs in 10 the donor and recipient was shown to be a major determinant of biopsy-proven rejection. Moreover, this 11 IL-6/IL-6R genetic risk score significantly improved risk prediction for rejection beyond currently used 12 clinical risk factors. In conclusion, our study provides genetic evidence for the potential efficacy of 13 targeting the IL-6 pathway in renal transplantation and encourages the study of IL-6 receptor inhibitors 14 in kidney donors in randomized controlled trials as a donor pretreatment strategy.

To our knowledge, our study is the first to demonstrate that IL6R polymorphisms in the donor 16 impact the risk of rejection after kidney transplantation. To sum up, we found that for each copy of the 17 C-allele in the donor the relative risk of biopsy-proven acute rejection decreased by 27% (90%-CI; 14-18 38%). In accordance with our results, the same allele (rs2228145-C) has been associated with 19 decreased risks of rheumatoid arthritis and coronary heart disease. 25,26 A recent study by Bovijn and 20 colleagues found that this IL6R variant was also associated with a lower risk of SARS-CoV-2 infection, CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint convincingly shows that the IL6R variant is associated with a lower risk of renal allograft rejection. We 1 postulate that this decrease in rejection rate is due to the amplification of sIL-6R combined with 2 circulating, endogenous, soluble gp130 acting as a buffer to neutralize IL-6, thereby suppressing 3 inflammation as well as decreasing allosensitization, invariably diminishing the risk of allograft rejection.

The impact of the IL6 174G/C polymorphism (rs1800795) on the risk of rejection among 5 transplantation patients has previously been investigated by several studies. 12,32-36 A recent metanalysis 6 of seven studies including 369 cases and 679 controls concluded that the recipient IL6 genotype was 7 not significantly associated with rejection, whereas a trend was seen for donor IL6 genotypes. 13 In our 8 transplant cohort of 1,271 patients we did not find such an association either. Yet, when we performed 9 a subgroup analysis for the sex of the donor, we observed a significant association between the IL6 10 SNP and rejection in male donors. This sex-related difference might also explain the conflicting results 11 by previous studies. Similar to our observations, others have reported a clear sex dimorphism in the 12 association of this IL6 polymorphism with the vulnerability to illnesses. 37-39 Overall, the associations with 13 this IL6 variant were stronger and predominantly found in men. Our study, therefore, highlights that sex 14 should be taken into account in transplantation as well as for cytokine-targeted therapies. Furthermore, 15 in conformity with our results, the C-allele of this IL6 SNP has also been associated with increased risks 16 of rheumatoid arthritis and cardiovascular disease in recent meta-analyses. 40-42 For rs1800795, the Gallele was initially said to increase IL-6 levels, however, recent work revealed that the C-allele of this 18 SNP leads to higher IL-6 expression in fibroblasts but not in leukocytes. 43 Brull et al. found different 19 kinetic profiles for IL-6 increase after surgery based on IL6 genotypes, which could explain previous 20 conflicting results. 44 Nevertheless, the overall increase in IL-6 was more profound in CC homozygotes.

Further in vivo evidence of the pro-inflammatory effects of the C-allele is demonstrated by the 22 association with higher serum levels of IL-6, C-reactive protein, and fibrinogen in multiple studies. [45] [46] [47] 23 Altogether, our study adds to a growing body of evidence that connects local production of IL-6 to the 24 allosensitization of recipients to renal allografts. 48,49 25 Tocilizumab, a humanized monoclonal antibody targeting the IL-6R, has been assessed for the 26 treatment of acute rejection, chronic ABMR, and transplant glomerulopathy following renal 27 transplantation. 50-52 Initially, a phase I/II trial was performed in 10 patients prior to kidney transplantation 28 that were unresponsive to desensitization with intravenous Ig and rituximab. 50 Tocilizumab, combined 29 with intravenous Ig, led to a significant reduction in DSA levels and appeared safe. Five patients were 30 transplanted and six-month protocol biopsies showed no acute rejection or transplant glomerulopathy.

Next, an open-label single-center trial was undertaken in 36 patients with chronic ABMR that were non-32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint responsive to intravenous Ig and rituximab. 51 Patient and renal allograft survival was 91% and 80% at 1 6 years, respectively, and this was found to be superior to historical controls. Furthermore, stabilization 2 of renal function was seen after 2 years. Finally, tocilizumab was investigated for the treatment of acute 3 rejection in an observational study of 7 kidney transplant recipients. 52 Renal function stabilized or 4 improved in all patients, but one patient had a potential hypersensitivity reaction, and another patient 5 developed cytomegalovirus esophagitis. A multicenter randomized control trial is currently underway. 53 6 Considering IL-6 inhibitors are already being tested in clinical trials, what, then, is the role for genetic 7 studies here? The results from our study provide important considerations for the design of these clinical 8 trials by identifying the following key issues for targeting IL-6 in renal transplantation: (i) Site of action; 9 (ii) Timing of treatment; (iii) Sex differences; and, (iv) Patient selection.

We found that genetic polymorphisms of the IL-6 signaling pathway in donors, but not recipients,

were associated with the risk of biopsy-proven rejection after kidney transplantation. These results

indicate that not circulating IL-6 in the recipient but local IL-6R expression and IL-6 production by the 13 donor kidney are key drivers of allosensitization to the kidney transplant. This potentially suggests that 14 therapies aimed at blocking IL-6/IL-6R interactions should focus on the donor kidney as the site of action.

Neutralizing IL-6R nanobodies (i.e., ALX-0061) could therefore be more effective than larger anti-IL-6R 16 (i.e., tocilizumab) or anti-IL-6 antibodies (i.e., clazakizumab), due to better tissue penetration of the 17 donor kidney. 4 Alternatively, the use of small interfering RNA (siRNA) could be a promising 18 approach. 54,55 The found association we found between donor genetics and transplant outcomes also 19 indicates that donor pre-treatment might be the optimal timing of treatment. Interventions within the 20 donor may protect against a proinflammatory reaction after transplantation, and therefore, donor pre-21 treatment could be a promising strategy to increase graft function and survival. 56 Conversely, donor pre-22 treatment is not possible until it is known whether other donor organs (i.e., the liver, heart, and lungs) 23 also benefit from targeting IL-6. Instead, treatment could be given during the preservation phase (i.e., 24 cold storage or machine perfusion), thereby targeting the donor kidney specifically. Finally, in this study,

we constructed an IL-6/IL-6R genetic risk score based on two SNPs in the donor and recipient. From a 26 prognostic perspective, this genetic risk score could be used for the prediction of patients at high risk of 27 allograft rejection. Furthermore, the genetic risk score may be used to identify renal transplant pairs that 28 could benefit from anti-IL-6 treatment.

Several limitations of our study warrant consideration. First, the associations found in this study 30 are expected to be causal. However, since our study is prospective, but observational in nature, it cannot 31 be proven by our results. Second, we only performed an analysis of individual functional SNPs and not 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint for IL6 and IL6R haplotypes. Third, measurements of IL-6 and sIL-6R were not performed in our cohort 1 due to the lack of serum samples, and genotypes could therefore not be correlated to systemic levels.

Finally, we could not investigate whether the association between the IL6 and IL6R variants differed for 3 TCR or ABMR, due to the lack of a standardized assay over the years for the determination of DSA. On 4 the other hand, major strengths of our study are the large sample size, robust statistical analysis (incl. 5 subgroup analysis), and the hard and clinically relevant endpoint, namely biopsy-proven rejection.

In conclusion, we found that IL6 and IL6R variants in the donor associate with the risk of 7 developing biopsy-proven rejection after renal transplantation. These findings imply potential efficacy of 8 targeting IL-6 signalling in renal transplantation. Ongoing, randomized controlled trials with IL-6 or IL-9 6R inhibitors are needed to identify the best settings, including the timing of intervention and patient 10 selection, in which these agents might be effective.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Genetic risk score

We created a genetic IL-6 and IL-6R risk score that assigns points for the presence of a risk-decreasing 29 or a risk-increasing allele in the donor and recipient. However, to take into account the strength of the 30 association of the SNPs with rejection, the point for the presence of an IL6 or IL6R SNP is multiplied by 31 the regression coefficient (= logarithm of the hazard ratio) creating a weighted risk score. A regression 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint coefficient is negative when an SNP is protective and the regression coefficient is positive when an SNP 1 is hazardous. The total sum of the IL6 or IL6R SNPs in both the donor and recipient creates the genetic 2 risk score. Next, we determined whether the genetic risk score improved the prediction of rejection 3 compared to only the IL6R SNP in the donor. Mann-Whitney-U test or the Student t-test for not-normally and normally distributed variables, 10 respectively, and categorical variables with the χ2 test. Log-rank tests were performed between groups 11 to assess the difference in the incidence of biopsy-proven rejection. Univariable analysis was performed 12 to determine the association of genetic, donor, recipient, and transplant characteristics with rejection.

The factors identified in these analyses were thereafter tested in a multivariable Cox regression.

14 Additionally, multivariable cox regression with a stepwise forward selection was performed. Harrell's C 15 statistic was used to assess the predictive value of the SNPs when added to the reference model. The The authors declare that the research was conducted in the absence of any commercial or financial 2 relationships that could be construed as a potential conflict of interest. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint 1 polymorphism directs IL-6 expression in fibroblasts but not selected other cell types. Proc. Natl. 

14 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Log-rank test was used to compare the incidence of biopsy-proven rejection between the groups. 1 Hazard ratios for the interleukin-6/interleukin-6 receptor genetic risk score among subgroups.

Forest plot of sub-analyses of the IL-6/IL-6R genetic risk score, demonstrating that the hazard ratios for 4 biopsy-proven rejection were consistent in different subgroups. The only exception was the donor origins 5 of the kidney allografts. The association between the IL-6/IL-6R genetic risk score and rejection was not 6 seen in kidney transplants from living donors. No significant interaction was seen between the IL-6/IL-7 6R genetic risk score and the different clinical variables of the subgroups. Tables   1   2   . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 Associations of interleukin-6 and interleukin-6 receptor polymorphisms in the donor with 2 rejection following kidney transplantation.

Data are presented as hazard ratio with 95% confidence interval (CI) and P-value. 

Multivariable cox regression was performed with a stepwise forward selection. Only variables that with 5 a P-value below 0.10 in the univariate analysis were included. Data are presented as hazard ratio with 6 95% confidence interval (CI) and P-value. In the final, the IL6R SNP (rs2228145-C, previously 7 rs8192284) In the donor, total number of HLA-mismatches, recipient age, the occurrence of delayed 8 graft function (DGF) and recipient sex were included, whereas dialysis vintage and warm ischemia time 9 were not. 10 11 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint Table 4 1 Associations of interleukin-6/interleukin-6 receptor genetic risk score with rejection following 2 kidney transplantation. Data are presented as hazard ratio with 95% confidence interval (CI) and P-value.

Model 1: crude model . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint 

Multivariable cox regression was performed with a stepwise forward selection. Only variables that with 5 a P-value below 0.10 in the univariate analysis were included. Data are presented as hazard ratio with 6 95% confidence interval (CI) and P-value. The IL-6/IL-6R genetic risk score, total number of HLA- . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint Table 6 1 Additive value of the interleukin-6/interleukin-6 receptor genetic risk score in with rejection . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.17.21255669 doi: medRxiv preprint

Renal transplantation

Interleukin 6 Family of Cytokines

IL-6: regulator of Treg/Th17 balance

Recent insights into targeting the IL-6 cytokine family in 15 inflammatory diseases and cancer

Interleukin-6: discovery of a pleiotropic cytokine